TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive NCAB Committee Approves Concepts For Recompetition Of CIDAC, Two Other Contracts July 1, 1983
TCL Archive Investigators Unlocking Drug Resistance Secrets, NCI Study, Bristol-Myers Meeting Reports Show November 28, 1986
